Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.